These days, there’s a focus on how to best expedite the clinical development process, leading to the adoption of adaptive trials. One area that might be overlooked? Data Management.
September 30, 2020
- Cancer Support: Contract Research Organizations, More Than a Vendor, a Partner In Drug Development.
- Advancing Bone and Sarcoma Cancer Research Through Robust In Vivo Models
- How the FDA’s Plausible Mechanism Framework Signals the Future of Precision Oncology
- What Makes Radioligand Therapy IND Strategy Fundamentally Different?
- Receptor Mediated Therapies in the Clinic: From Targeting to Impact
Cancer Support: Contract Research Organizations, More Than a Vendor, a Partner In Drug Development.
Developing cancer therapies is an incredibly complex, costly, and highly regulated journey. To navigate this challenging terrain, pharmaceutical and ...
Advancing Bone and Sarcoma Cancer Research Through Robust In Vivo Models
Bone cancers and soft tissue sarcomas represent a diverse group of rare malignancies arising from mesenchymal tissues including bone, muscle, fat, ...
How the FDA’s Plausible Mechanism Framework Signals the Future of Precision Oncology
The FDA’s newly announced Plausible Mechanism Framework marks an important step toward aligning regulatory pathways with the realities of modern ...
Get Started
Contact Us Today!
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
